P180 Immune-Oncology (IO) – Tyrosine Kinase Inhibitor (TKI) or IO-IO as first-line treatment in metastatic renal cell carcinoma: What is better in real-world practice?

O. Stativko, В. Н. Галкин, E. Tsareva et al.|European Urology Open Science|2024

Cited by 0